Long noncoding RNA BSN-AS2 induced by E2F1 promotes spinal osteosarcoma progression by targeting miR-654-3p/SYTL2 axis

Xianwei Zhou; Jitian Li; Junyan Teng; Yufeng Liu; Di Zhang; Linyun Liu; Wenming Zhang

doi:10.1186/s12935-020-01205-y

Long noncoding RNA BSN-AS2 induced by E2F1 promotes spinal osteosarcoma progression by targeting miR-654-3p/SYTL2 axis

Cancer Cell Int. 2020 Apr 25:20:133. doi: 10.1186/s12935-020-01205-y. eCollection 2020.

Authors

Xianwei Zhou¹, Jitian Li², Junyan Teng³, Yufeng Liu¹, Di Zhang¹, Linyun Liu³, Wenming Zhang¹

Affiliations

¹ Spine Surgery, Luoyang Orthopedic Hospital of Henan Province, No. 100 Yongping Road, Zhengzhou, 450000 Henan China.
² Laboratory of Bone Tumor, Luoyang Orthopedic Hospital of Henan Province, Zhengzhou, 450000 Henan China.
³ Department of Osteoarthrosis & Health Management Center, Luoyang Orthopedic Hospital of Henan Province, Zhengzhou, 450000 Henan China.

Abstract

Spinal osteosarcoma (OS) is a rare and aggressive malignancy. Long noncoding RNA (lncRNA) BSN-AS2 has been shown to be an oncogenic gene in several cancers. However, the role and function of BSN-AS2 in spinal OS were unfamiliar. Our study identified that BSN-AS2 expression was boosted in spinal OS tissues and cell lines. Transcription factor E2F1 induced the upregulation of BSN-AS2 expression in spinal OS cells. Afterwards, loss-of-function assays indicated that BSN-AS2 depletion reduced cell proliferation, migration and invasion as well as promoted cell apoptosis in spinal OS. Thereafter, RIP, RNA pull down and luciferase reporter assays manifested BSN-AS2 could sponge miR-654-3p in spinal OS. After that, the binding effect of between miR-654-3p and SYTL2 was proved. Finally, rescue experiments illustrated that miR-654-3p inhibition or SYTL2 overexpression could counteract the inhibitory effect caused by BSN-AS2 deficiency on spinal OS progression. In conclusion, the availability of miR-654-3p was antagonized by E2F1-induced BSN-AS2 for SYTL2-meidated spinal OS progression.

Keywords: BSN-AS2; E2F1; SYTL2; Spinal osteosarcoma; miR-654-3p.